Contact
A response within 24 hours, no intermediary.
Briefly describe your study to us. We will get back to you with an initial methodological assessment and budgetary framework — free and without obligation.
Khadija will reply.
Describe your project — we will get back to you within 24 business hours with a personalised framework.
Contact us directly
Response guaranteed within 24 business hours
Directly from a senior team member — not a sales representative.
FAQ
Before reaching out, you may be wondering…
How quickly do you respond?
We guarantee a first response within 24 business hours, directly from a senior team member — not a sales representative.
Do you work with first-time sponsors?
Yes. We regularly support biotechs on their first clinical trial, MedTechs preparing their first CE marking, or academic researchers running their first investigator-initiated study. Our approach: upfront methodological scoping to secure the protocol before the go.
Can you manage an international study?
Yes. Our Exagis CDMS is available in 11+ languages and we have deployed multicentre studies in more than 12 countries. Our deliverables comply with EMA and FDA requirements (CDISC SDTM/ADaM, define.xml, 21 CFR Part 11 audit trail).
Is your data hosted in France?
Yes. Our infrastructure is HDS-certified (Hébergeur de Données de Santé), with Tier 3 data centres in metropolitan France. Your patient data never leaves French territory.
How much does a project with Axiodis cost?
The budget depends on several parameters: study type (interventional / observational), number of patients, number of sites, technology modules required (CDMS only, CDMS + ePRO, randomisation), scope of services (data management only or full-service biostatistics). After an initial discussion, we provide an indicative budgetary framework within 24 business hours.
What is the difference between Axiodis and a large CRO?
Three concrete differences: (1) a single contact per study, from kick-off to database lock — not a replaceable project manager; (2) a proprietary Exagis platform configurable within days, with no licence surcharge; (3) a human-scale team based in France combining biostatisticians, data managers and project managers under one roof.
Are you compliant with FDA requirements?
Yes. Exagis complies with 21 CFR Part 11 (audit trail, electronic signatures, access controls). Our statistical methodology adheres to CDISC standards (SDTM, ADaM, define.xml, reviewer's guide) expected by the FDA. Our biostatistical analyses are conducted under SAS in a GAMP5-validated environment.
Are you part of a group?
Axiodis CRO has been a subsidiary of the Oxurion Group (Euronext Brussels: OXUR) since 2025. This integration gives us the means to invest in R&D — particularly in AI applied to clinical data (digital twins, automated quality control) — while preserving our human-scale approach and operational independence.